A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

NCT ID: NCT07255898

Last Updated: 2025-12-01

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-31
• Study Completion Date: 2027-12-31

Brief Summary

This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-M24D1 in patients with relapsed or refractory multiple myeloma and other hematologic malignancies.

Detailed Description

The study is divided into two phases: a dose escalation phase (Phase Ia) and an expansion cohort phase (Phase Ib).

Conditions

Multiple Myeloma; Hematologic Malignancies

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BL-M24D1

Participants receive BL-M24D1 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

BL-M24D1

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 2 weeks.

Interventions

BL-M24D1

Administration by intravenous infusion for a cycle of 2 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Voluntarily sign the informed consent form and comply with the protocol requirements;

2. Gender is not restricted;

3. Age: ≥18 years and ≤75 years (Phase Ia); ≥18 years (Phase Ib);

4. Expected survival time ≥3 months;

5. Histologically and/or cytologically confirmed multiple myeloma or other hematologic malignancies that have failed standard treatment or for which no standard treatment currently exists;

6. Must have measurable indicators as defined by the protocol;

7. Physical condition score ECOG 0 or 1;

8. Toxicity from previous antitumor treatments has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;

9. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

10. Organ function levels must meet the requirements;

11. Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × ULN;

12. For premenopausal women with childbearing potential, a pregnancy test must be conducted within 7 days before starting treatment, the serum pregnancy test must be negative, and they must not be breastfeeding; all enrolled patients (regardless of gender) should adopt adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria

1. Subjects with central nervous system involvement, etc.;

2. Use of chemotherapy, biologics, immunotherapy, etc., within 4 weeks prior to the first dose or within 5 half-lives;

3. History of severe heart disease;

4. QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block;

5. Active autoimmune diseases and inflammatory diseases;

6. Diagnosis of other malignancies within 5 years prior to the first dose;

7. Hypertension poorly controlled by two antihypertensive medications;

8. Patients with poorly controlled blood glucose;

9. Unstable thrombotic events requiring therapeutic intervention within 6 months prior to the first dose;

10. Lung diseases defined as ≥ Grade 3 according to CTCAE v5.0; history of interstitial lung disease requiring hormone treatment, etc.;

11. Patients with peripheral neuropathy ≥ Grade 3 or persistent ≥ Grade 2 peripheral neuropathy with pain;

12. Patients with a history of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of BL-M24D1;

13. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

14. Human immunodeficiency virus antibody positivity, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;

15. Active infection requiring systemic treatment within 4 weeks prior to the first study drug administration, etc.;

16. Pleural, abdominal, pelvic, or pericardial effusion requiring drainage and/or accompanied by symptoms within 4 weeks prior to the first study drug administration;

17. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to the first study drug administration;

18. Participation in another clinical trial within 4 weeks prior to the first dose;

19. Pregnant or breastfeeding women;

20. Patients who received live vaccines within 30 days prior to the first dose;

21. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Countries

China

Central Contacts

Sa Xiao, PHD

Role: CONTACT

xiaosa@baili-pharm.com

15013238943

Facility Contacts

Ting Niu

Role: primary

Other Identifiers

BL-M24D1-103

Identifier Type: -

Identifier Source: org_study_id